Congress Passes Breast/Cervical Cancer Bill

Publication
Article
OncologyONCOLOGY Vol 14 No 12
Volume 14
Issue 12

Congress finally passed a bill (H.R. 4386/S. 662) that allows states to provide medical treatment for women with breast and cervical cancer. At their option (there is no requirement), states can treat women who have tested positive in a screening

Congress finally passed a bill (H.R. 4386/S. 662) that allows states to providemedical treatment for women with breast and cervical cancer. At their option(there is no requirement), states can treat women who have tested positive in ascreening program run by the Centers for Disease Control and Prevention (CDC).Frequently, these screening programs are located at community health clinics inpoor urban areas and on Native American reservations, clinics funded by theHealth Resources and Services Administration (HRSA). Nearly 2 million women havebeen screened since 1990. The budget in fiscal year 2000 for this NationalBreast and Cervical Cancer Early Detection Program was $167 million. In thepast, many of the women diagnosed with cancer had nowhere to turn for medicaltreatment because they were uninsured. The Breast and Cervical Cancer TreatmentAct opens up a treatment avenue for some of them. States will be able to providetreatment through Medicaid, and will get an enhanced federal matching grant forestablishing that treatment program.

Recent Videos
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Oncologists are still working on management strategies for neuropathy; a common adverse effect related to chemotherapeutics for ovarian cancer.
Genetic testing information can be used to risk-stratify ovarian cancer survivors for breast cancer, particularly those with BRCA1 or BRCA2 mutations.
Genetic testing for ovarian cancer may help inform treatment decisions for patients with advanced disease, particularly regarding PARP inhibitor use.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content